ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
8,003.30
-0.18%
S&P ASX All Technology
3,173.80
0.28%
Brent Oil
84.075
-0.31%
US Dollar vs AUD
1.48271
0.28%
Bitcoin
64,576.72
-0.42%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. PureTech Health PLC (PRTC)

  7. PureTech Health PLC (PRTC) News

PRTC

PureTech Health (PRTC)

PureTech Health PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PRTC
DateTimeSourceHeadlineSymbolCompany
27/02/202418:00Business WirePureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in JapanNASDAQ:PRTCPureTech Health PLC
05/01/202408:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRTCPureTech Health PLC
03/01/202423:00Business WirePureTech to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:PRTCPureTech Health PLC
23/12/202301:13Business WirePureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 BillionNASDAQ:PRTCPureTech Health PLC
20/12/202318:00Business WirePureTech Year End Update and Outlook for 2024NASDAQ:PRTCPureTech Health PLC
07/12/202322:00Business WirePureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023NASDAQ:PRTCPureTech Health PLC
30/11/202302:17Business WirePureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of SchizophreniaNASDAQ:PRTCPureTech Health PLC
17/11/202318:00Business WirePureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in SchizophreniaNASDAQ:PRTCPureTech Health PLC
14/11/202318:00Business WirePureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy VolunteersNASDAQ:PRTCPureTech Health PLC
03/11/202307:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRTCPureTech Health PLC
17/10/202317:00Business WirePureTech to Present at Two Upcoming Investor ConferencesNASDAQ:PRTCPureTech Health PLC
11/10/202322:00Business WirePureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults at CHEST Annual MeetingNASDAQ:PRTCPureTech Health PLC
04/10/202322:05Business WirePureTech Founded Entity Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track DesignationNASDAQ:PRTCPureTech Health PLC
28/09/202321:38Business WireKarXT, invented at PureTech, submitted for FDA Approval in SchizophreniaNASDAQ:PRTCPureTech Health PLC
27/09/202316:05Business WirePureTech Announces the Appointment of Robert Lyne as Chief Portfolio OfficerNASDAQ:PRTCPureTech Health PLC
07/09/202306:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRTCPureTech Health PLC
29/08/202320:33Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRTCPureTech Health PLC
29/08/202316:00Business WirePureTech Health plc – Half-Year ReportNASDAQ:PRTCPureTech Health PLC
22/08/202316:00Business WirePureTech Health: Notice of Half-Yearly ResultsNASDAQ:PRTCPureTech Health PLC
03/08/202306:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRTCPureTech Health PLC
01/08/202321:00Business WirePureTech Awarded up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-associated Tremor/Ataxia SyndromeNASDAQ:PRTCPureTech Health PLC
07/07/202306:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRTCPureTech Health PLC
21/06/202321:00Business WirePureTech Initiates Phase 2a Clinical Trial of LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety DisordersNASDAQ:PRTCPureTech Health PLC
14/06/202302:40Business WireResults of PureTech's Annual General MeetingNASDAQ:PRTCPureTech Health PLC
13/06/202306:31Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:PRTCPureTech Health PLC
03/06/202306:32Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:PRTCPureTech Health PLC
24/05/202321:00Business Wire PureTech to Present at the Jefferies Healthcare ConferenceNASDAQ:PRTCPureTech Health PLC
09/05/202316:00Business WirePureTech Founded Entity Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease WeekNASDAQ:PRTCPureTech Health PLC
04/05/202316:00Business WirePureTech Founded Entity Akili Announces Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based TherapeuticNASDAQ:PRTCPureTech Health PLC
04/05/202306:32Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:PRTCPureTech Health PLC
 Showing the most relevant articles for your search:NASDAQ:PRTC

Your Recent History

BIT
P1TM88
BNP Paribas Issuance
NASDAQ
CCLP
CSI Compressco
BIT
P1SY77
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved